BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
about
Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Acral-acroma malignant melanoma. A clinical case report and review of literature.Cancer: Towards a general theory of the target: All successful cancer therapies, actual or potential, are reducible to either (or both) of two fundamental strategies.BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting
P2860
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
BRAF plus MEK-targeted drugs: ...... BRAF-mutant advanced melanoma.
@en
type
label
BRAF plus MEK-targeted drugs: ...... BRAF-mutant advanced melanoma.
@en
prefLabel
BRAF plus MEK-targeted drugs: ...... BRAF-mutant advanced melanoma.
@en
P2860
P1476
BRAF plus MEK-targeted drugs: ...... BRAF-mutant advanced melanoma.
@en
P2093
Paola Queirolo
P2860
P2888
P356
10.1007/S10555-017-9660-6
P577
2017-03-15T00:00:00Z
P6179
1084025475